Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks tank! Also lovein the DD contributions by you and others. NHMD will move big. Everybody knows inventory is key when moving into multiple large grocery stores.
The directions they took to get to this point weren't accidental. Just part of getting to a point where they knew it was time to work into regional stores and they're confident about the product margin, shelf stability, and quality. Now it's just time to get it in front of the consumers. But not until they can fill those orders! Inventory inventory inventory. Got to do it right.
Indeed. Imo NHMD will finish next week in the mid 20's with high of low 30's unless we get updates. This time of year for OTC is standrd noise and selling. I will start buying again in January:)
Btw, made gluten free pancakes for the wife this morning. Was in such a hurry, and all that early morning math to make a smaller batch and all that clean up....sheesh, I'd rather still be half asleep and just heat up the pan while I hook up a quick cup of instant coffee. I'd pay extra for that convenience. i sure hope NATE comes back with that gluten free version again.
For others that got some in the teens, congrats!!
Yeah SNAK!! Weeeeeeee! BreakOUT
Riding it out now.
O/S here now? Thank you.
Thanks. Very robust post. Pure facts.
No one has produced ANY...ANY evidence that this is a scam. Even you surfkast! A chart certainly is not proof LMAO! That is because it is not a "scam".
Now if the pancake batter from NATE's I have been ordering had nothing in it, or something other than batter, then the noise would have purchase on this bullshit scam claims.
It is real, edible, and delicious SO..not a scam!!!
You can say things like
"Overpriced"
Or
"Overvalued"
And I wouldn't agree, but that would at least be an acceptable contribution for actual discourse.
Nope.. still make ZERO sense. What's with all the unintelligible rage anyway?
LMAO. I know right! R/S?! Anyone that even knows what those letters mean, and can read a filing, knows that an R/S here is soooooo far out of the question that it's a laughable suggestion.
But, it'll be made. Noise pays the bills for some I guess. LOL
No one has produced ANY...ANY evidence that this is a scam. That is because it is not. That simple folks.
Now if the pancake batter from NATE's I have been ordering had nothing in it, or something other than batter, then the noise would have purchase on this bull shit scam claims. But, to end this "scam" crap,
It is real, edible, and delicious SO..not a scam!!!
You can say things like
"Overpriced"
Or
"Overvalued"
And I wouldn't agree, but that would at least be an acceptable contribution for actual discourse.
Wow! The lies and misinformation by
NOISE is way out there!!
There will always be noise when true information takes effort to FACT check.
For example. See the extra work it takes to silence the ongoing lies (yes lies because after correcting the same folks over and over, who use the same script, with FACTS, they still repeat it) about share selling scam and enrichment here http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127021239
Pretty clear this is NOT a scam, nor quick money. Nor is anything illegal happening LOL. It's a real company with recently extinguished toxic debt with sales and soon regional distribution. Undervalued and over attacked by the usual .
Do DD and you'll see.
NEWS OUT---
Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer
PR Newswire
SAN DIEGO, December 7, 2016
SAN DIEGO, December 7, 2016 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBPP) In a recent study published in the International Journal of Molecular Sciences a team of scientists in Guangzhou, China[1] have demonstrated that expression of NR2F6 in patients with early cervical cancer correlates with poor prognoses. These scientists tested for NR2F6 in patient's cervical cancer tissue as well as in the normal tissue surrounding each of their tumors.
"This is an interesting study and the first that I am aware of that has tested for NR2F6 in patients with cervical cancer," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen BioPharma, Inc. "What they found was that those patients who had high amounts of NR2F6 protein expressed in their tumors died much faster than those patients with low or no expression of NR2F6 protein. To me, this is an important validation of the role of NR2F6 in cancer in humans, rather than simply animal models, and implies that inhibiting NR2F6 may be beneficial for these patients. While the study didn't go into the mechanism of action, it did show clear correlation and statistical significance indicating that NR2F6 expression is a potential biomarker for early cervical cancer."
Regen BioPharma, Inc. is developing small molecule inhibitors and activators of NR2F6. Inhibitors (which inhibit the expression of NR2F6) are expected to be useful in the treatment of various cancers and activators (which activate the expression of NR2F6) in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis.
"This journal article provides empirical evidence that supports our belief that inhibiting NR2F6 is a key to treating cancer in patients," noted David Koos, Regen's Chairman & CEO. "Our company sees an opportunity to enhance both the longevity and quality of life through further developing its NR2F6 small molecule therapies for treating cancer and autoimmune diseases."
Regen is also party to an agreement whereby Zander Therapeutics, Inc. has been granted by Regen an exclusive worldwide right and license for the development and commercialization of NR2F6 intellectual property controlled by Regen for non-human veterinary therapeutic use. Controlling NR2F6 in dogs and cats may be effective in treating diseases such cancer and arthritis at the veterinary level.
Regen believes that, in addition to its human therapeutics which may be developed by Regen, licensing fees related to veterinary applications of NR2F6 which may be developed by Zander may provide an additional income stream to Regen.
Zander Therapeutics Inc. is a wholly owned subsidiary of Entest BioMedical Inc. (PINKS: ENTB). David R. Koos serves as Chairman and Chief Executive Officer of Regen, Entest Biomedical, Inc. and Zander Therapeutics.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
About Zander Therapeutics Inc.:
Zander Therapeutics, Inc. is a veterinary biotechnology company that is wholly owned by Entest BioMedical Inc. (a publicly traded company -- PINK: ENTB). Zander is primarily focused on developing small molecule therapies for treating autoimmune disorders and canine cancer (dogs). Currently the Company is developing products treating blood disorders using small molecules based on NR2F6 under an exclusive license agreement for veterinary use from Regen BioPharma Inc. (OTCQB: RGBP), gene silencing for treating cancer with immunotherapy, modulating key molecular processes in cancer stem cell through its patent molecular targeting approaches and repairing damaged bone marrow in animals with aplastic anemia and bone marrow suppression due to side effects of chemotherapy/radiotherapy treated cancer patients.
http://www.zandertherapeutics.weebly.com/
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
[1]Int. J. Mol. Sci. 2016, 17, 1694
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
There will always be noise when true information take effort to FACT check. For example. See the extra work it takes to silence the ongoing lies (yes lies because after correcting the same folks over and over with the same script with FACTS, they still spread is information) about share selling scam and enrichment here http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127021239
Pretty clear this is NOT a scam, nor quick money. It's a real company with recently extinguished toxic debt with sales and soon regional distribution. Undervalued and over attacked by the usual .
Do real DD and you'll see.
Yep. I completely agree. Cheers to anyone who can make money despite his shameful style. GL!
What a day! Gulp! LOL not the first time I rode out a low. No worries on my end. As i229 has pointed out, we know things are still moving forward and sales in 2017 will provide the fundamentals to back that up. :)
Wow!! Checked on DD...this is THIN and fundamentally packed with good value! No doubt this has very big possibility to run. Nice gem here!
GL
We've gone through this already, along with the other corrected DD.
TD Ameritrade Apex members will NOT be charged the $38 fee to convert the preferred shares.
Oh brother. So much bad info in the noise. Bottom line. Conversion to commons are free! Nothing complicated or (expensive) about it
Surfkast--"ta is gagged"---->WRONG!
Blatantly and Nefariously
ALL BUYS TODAY! Well would you look at that!!
The noise here gets quite silly.
Ask at 32 now. Slapping the way to go now. Unless that bid comes up. Can't see any large retail positions exiting at this level.
Good word!! Now that makes sen$e!!
:)
Well that last slap did it. VFIN back off the ask again. Not sure why V appeared in first place. CDEL garbage now. Won't take much to slap him out.
Sorrry. Not buying the noise. It's obvious there is short interest.
Trades are going through to the fifth digit at a discount for me. And at the same time there is noise here.
Just the same ol bla bla about "scam"
Hmm. Good swing at v. Got my eye on it
NHMD:)
A simple fact. NOISE can drown truth
NATE's product produced and sold NOW!
Low float
Distribution coming
It's that simple.
I thought that too. I'd be inclined to help but not at the top of the ask LOL. After seeing that 20mil bid a few days back, I'm ballLess. Don't want to lose those shares!
I see NHMD making a big run, to rival the last one, into January and February. Just a guess.
See that. Agree, one tic lower to induce the shuffle. Those 500k would be a shame to lose right now. (Not mine btw). The 26% spread is to attract that shark bait..or..I mean...liquidity LOL. The whopping 2 mms we got at NHMD are swimming in the water goin hungry.
Wow...never mind CDEL beat me to it LOL
I kind of want to toy with VFIN to see what gives. But maybe tomorrow will be better. Definitely VFIN asking bellow the last price to open the day is a gesture away from any kind of fresh shares hitting. My only sense of it is as u suggested, to post a low for some kind of conversion?
Bid at 26 now with CDEL and last @ 00236. LOL!
That's a fact fink, I've received the same odd discounts from time to time. The manipulation is just so easy to see. It's so organized that it sticks out like a sore thumb. It like a mouse trap that's all cheese and no trap LOL!
One thing is certain, I'm getting antsy for that catalyst from NATE's . I want to see how those mms manage the next big move! With VFIN rolling the dice, I'd expect another move up to the 40s by next Tuesday without news.
Interesting today. A VERY tight share structure with that float locked up at this level especially. Funny to watch the local mms make effort here. Crazy how just watching numbers on L2 can create its own sitcom storyline LOL.
I'm in for a few hundredK more tomorrow if it keeps up:)...you know, why the heck not!?
This IS going up...oh, in my confident opinion of course :)
NHMD!!
Yep!! Especially after that mm 5th dig
400share sellLMAO VFIN DUMBDUMB
Very interesting to see nonetheless. Thin on both sides . 3 ways at worst, It'll cause a bid to build, or cause an attractive buying dip if dump (assuming he's holding lots of shares of which he may not be), or some savvy buyers will work the ask until he dries up.
All in all, not worried...just boring LOL
"Wonder why he opened at .0029 and not .0034? "
My thought as well. Very far outside what VFIN has done in the past. I don't think it's a new dilution move or note.
November 30, 2016 - 06:40 PM EST
House passes medical cures bill
House passes medical cures bill
The House on Wednesday passed a medical innovation bill aimed at curing diseases, with the measure securing bipartisan support after months of negotiations.
The legislation, known as the 21st Century Cures Act, passed 392-26. It seeks to speed up the Food and Drug Administration’s approval of new drugs while investing new money in medical research.
The package also includes a range of other healthcare priorities, including $1 billion over two years to fight the epidemic of opioid addiction and $1.8 billion for Vice President Biden’s cancer “moonshot.”
The opioid money releases some pressure from a long-running dispute between the parties. Congress passed a bipartisan opioid bill before the election, but Democrats criticized that measure for lacking funding.
The cures legislation also includes a mental health portion that seeks to reorganize and improve accountability for government mental health programs.
Republicans have portrayed the mental health bill, sponsored by Rep. Tim Murphy (R-Pa.), as their response to mass shootings, though that messaging has been emphasized less now that it is part of a larger package.
Democrats agree reforms are needed in mental health, though they note that the bill lacks funding. They say the bigger policy response to mass shootings should be gun control.
House leaders are hoping that the bipartisan vote Wednesday puts pressure on the Senate, which is expected to take up the cures bill sometime before leaving town next month.
The bill faces a bumpier path in the upper chamber, where Sens. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.) have blasted it as a giveaway to pharmaceutical companies.
Still, enough Democrats are expected to support the measure to get it across the finish line.
“This bill, which expedites the approval of drugs and devices, includes literally billions of dollars in additional spending for health research so that we can find the cures and the answers to what patients are demanding today,” said House Energy and Commerce Chairman Fred Upton (R-Mich.), the measure’s main sponsor.
The White House gave the measure a boost on Tuesday night by announcing that it “strongly” supports passage, pointing in particular to the opioid funding and the funding for the cancer moonshot.
The liberal detractors note that the new research funding, which is helping to bring some Democrats on board, is not mandatory funding, meaning it is not guaranteed.
Still, the $4.8 billion over 10 years is set aside in a separate fund and not subject to the usual budget caps.
Sanders and Warren have denounced the bill as helping out pharmaceutical companies, in part by lowering the FDA’s regulations for approving their new drugs, while doing nothing to deal with the hot-button issue of high drug prices.
Some consumer groups have also criticized the measure, fearing that in speeding up the FDA’s approval process, it would lower safety standards.
The measure allows for ideas like sometimes using “real world evidence,” rather than more rigorous and time-consuming clinical trials, in drug approvals.
Rep. Frank Pallone (D-N.J.), a lead negotiator on the bill in the House, rejected criticisms of the FDA changes.
“It’s just a way of trying to address these cures in a more effective way, the way the public has asked for, without sacrificing any safety,” Pallone said.
The mental health portion of the legislation establishes a new assistant secretary for mental health in the Department of Health and Human Services as well as a chief medical officer. Murphy argues that these positions will bring more accountability and medical knowledge to the Substance Abuse and Mental Health Services Administration, an agency he has criticized as ineffective.
The bill also authorizes grants for areas like suicide prevention.
The mental health measure is significantly scaled down from the more sweeping version originally proposed by Murphy, though. It does not lift restrictions on Medicaid paying for care at mental health facilities, which would have cost billions of dollars.
The measure also includes elements from a companion mental health bill in the Senate from Sens. Chris Murphy (D-Conn.) and Bill Cassidy (R-La.).
Both the Cures and mental health portions of the bill come after more than a year of bipartisan negotiations.
http://thehill.com/policy/healthcare/308168-house-passes-medical-cures-bill
Still trending up! :)
Dang, even with evil V playing today. Even if the float did increase today, only by peanuts. We'll see how the rest of the week goes, but I'm sure we continue the trend and (since we saw VFIN, we may see an 8k by next week). But I can't think of any reason VFIN did show today.
LOL..it always is.
Great move on that retail to whom ever got those mil. Certainly easy to see where this is headed :)
NO WAY, am I getting rid of any shares down here. But not that I had to say that. Easy choice
Well said. Agree on every point. Yes, shares at this price are great for new eyes catching up on DD.